Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.

Pires de Mello CP, Drusano GL, Adams JR, Shudt M, Kulawy R, Brown AN.

Eur J Pharm Sci. 2018 Jan 1;111:443-449. doi: 10.1016/j.ejps.2017.10.027. Epub 2017 Oct 25.

2.

Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.

Louie A, Vanscoy B, Liu W, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2013 Dec;57(12):5946-60. doi: 10.1128/AAC.02616-12. Epub 2013 Sep 16.

3.

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.

Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1170-81. doi: 10.1128/AAC.05383-11. Epub 2011 Dec 12.

4.

Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1229-39. doi: 10.1128/AAC.01109-10. Epub 2011 Dec 12.

5.

Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2012 Feb;56(2):682-6. doi: 10.1128/AAC.05664-11. Epub 2011 Nov 14.

6.

Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.

Cardone KE, Grabe DW, Kulawy RW, Daoui R, Roglieri J, Meola S, Drusano GL, Lodise TP.

Antimicrob Agents Chemother. 2012 Feb;56(2):725-30. doi: 10.1128/AAC.05515-11. Epub 2011 Nov 14.

7.

Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Louie A, Vanscoy BD, Heine HS 3rd, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):513-7. doi: 10.1128/AAC.05724-11. Epub 2011 Nov 7.

8.

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.

Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):258-70. doi: 10.1128/AAC.05005-11. Epub 2011 Oct 24.

9.

Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, Vanscoy B, Defiglio H, Fikes S, Brown D, Drawz SM, Kulawy R, Louie A.

Antimicrob Agents Chemother. 2012 Jan;56(1):231-42. doi: 10.1128/AAC.05252-11. Epub 2011 Oct 17.

10.

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model.

Drusano GL, Liu W, Kulawy R, Louie A.

Antimicrob Agents Chemother. 2011 Nov;55(11):5300-5. doi: 10.1128/AAC.00502-11. Epub 2011 Sep 12.

11.

Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.

Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A.

MBio. 2011 Jul 12;2(4):e00108-11. doi: 10.1128/mBio.00108-11. Print 2011.

12.

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Török ME, Van Wart SA, Mai PP, Reynolds DK, Caws M, Dung NT, Hien TT, Kulawy R, Farrar J, Ambrose PG.

Antimicrob Agents Chemother. 2011 Jul;55(7):3244-53. doi: 10.1128/AAC.00064-11. Epub 2011 Apr 18.

13.
14.

Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.

Louie A, Vanscoy B, Liu W, Kulawy R, Brown D, Heine HS, Drusano GL.

Antimicrob Agents Chemother. 2011 Jun;55(6):2623-8. doi: 10.1128/AAC.01374-10. Epub 2011 Apr 12.

15.

Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.

Lin HY, Landersdorfer CB, London D, Meng R, Lim CU, Lin C, Lin S, Tang HY, Brown D, Van Scoy B, Kulawy R, Queimado L, Drusano GL, Louie A, Davis FB, Mousa SA, Davis PJ.

PLoS Comput Biol. 2011 Feb 3;7(2):e1001073. doi: 10.1371/journal.pcbi.1001073.

16.

Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.

Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1740-6. doi: 10.1128/AAC.01628-10. Epub 2011 Jan 24.

17.

Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.

Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53. doi: 10.1128/AAC.01629-10. Epub 2011 Jan 24.

18.
19.

The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2010 Jun;54(6):2646-54. doi: 10.1128/AAC.00065-10. Epub 2010 Apr 5.

20.

Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.

Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2010 Jun;54(6):2638-45. doi: 10.1128/AAC.01721-09. Epub 2010 Mar 22.

21.

Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.

Drusano GL, Okusanya OO, Okusanya AO, van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2009 Nov;53(11):4718-25. doi: 10.1128/AAC.00802-09. Epub 2009 Aug 17.

22.

Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.

McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2009 Jun;53(6):2375-81. doi: 10.1128/AAC.00167-09. Epub 2009 Apr 13.

23.

Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.

Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3325-30. doi: 10.1128/AAC.00006-09. Epub 2009 Apr 13.

24.
25.

Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, Kulawy R, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2008 Nov;52(11):3973-9. doi: 10.1128/AAC.00453-08. Epub 2008 Aug 25.

26.

In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.

Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL.

Antimicrob Agents Chemother. 2007 Nov;51(11):3988-4000. Epub 2007 Sep 10.

27.

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A.

Antimicrob Agents Chemother. 2007 Mar;51(3):968-74. Epub 2006 Dec 28.

28.

Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

Chen YC, Gotzkowsky SK, Nafziger AN, Kulawy RW, Rocci ML Jr, Bertino JS Jr, Kashuba AD.

Br J Clin Pharmacol. 2006 Aug;62(2):187-95.

29.

Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product.

Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr.

J Clin Pharmacol. 2005 Jun;45(6):614-9.

PMID:
15901742
30.

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr.

J Clin Pharmacol. 2002 Apr;42(4):376-82.

PMID:
11936561
31.

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.

Streetman DS, Kashuba AD, Bertino JS Jr, Kulawy R, Rocci ML Jr, Nafziger AN.

Pharmacogenetics. 2001 Jun;11(4):349-55.

PMID:
11434513
32.

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.

Kashuba AD, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN.

Clin Pharmacol Ther. 1998 Sep;64(3):269-77.

PMID:
9757150
33.

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr.

Clin Pharmacol Ther. 1998 Sep;64(3):257-68.

PMID:
9757149

Supplemental Content

Loading ...
Support Center